RU2019105539A - Композиция, содержащая буфер - Google Patents
Композиция, содержащая буфер Download PDFInfo
- Publication number
- RU2019105539A RU2019105539A RU2019105539A RU2019105539A RU2019105539A RU 2019105539 A RU2019105539 A RU 2019105539A RU 2019105539 A RU2019105539 A RU 2019105539A RU 2019105539 A RU2019105539 A RU 2019105539A RU 2019105539 A RU2019105539 A RU 2019105539A
- Authority
- RU
- Russia
- Prior art keywords
- group
- targeting agent
- acid
- radioactive metal
- chelated
- Prior art date
Links
- 230000008685 targeting Effects 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 16
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 12
- 239000002184 metal Substances 0.000 claims 12
- 230000002285 radioactive effect Effects 0.000 claims 12
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 12
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000005711 Benzoic acid Substances 0.000 claims 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 6
- 235000010233 benzoic acid Nutrition 0.000 claims 6
- 239000001530 fumaric acid Substances 0.000 claims 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 6
- 239000011976 maleic acid Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000001384 succinic acid Substances 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- 241001181114 Neta Species 0.000 claims 1
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical group OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
- A61K51/048—DTPA (diethylenetriamine tetraacetic acid)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
Claims (23)
1. Композиция, включающая:
(a) хелатированный нацеливающий агент, который является конъюгатом хелатной группы и нацеливающей группы; и
(b) по меньшей мере один вид буфера, выбранного из группы, состоящей из бензойной кислоты, малеиновой кислоты, фумаровой кислоты, янтарной кислоты и их солей,
причем композиция используется для формирования комплекса между радиоактивным металлом, выбранным из группы, состоящей из 90Y, 153Sm, 165Dy, 165Er, 166Ho и 177Lu, и хелатированным нацеливающим агентом.
2. Композиция по п.1, в которой радиоактивный металл выбран из группы, состоящей из 90Y и 177Lu.
3. Композиция по п.1, в которой хелатная группа включает хелатную группу, имеющую структуру DOTA, структуру DTPA или структуру NETA.
4. Композиция по п.1, в которой хелатная группа выбрана из группы, состоящей из следующих хелатных групп:
5. Композиция по п.1, в которой нацеливающая группа выбрана из группы, состоящей из низкомолекулярного соединения, пептида, белка, антитела, фрагмента антитела и нуклеиновой кислоты.
6. Композиция по п.1, в которой хелатированный нацеливающий агент и буфер хранят в одном и том же сосуде.
7. Композиция по п.1, в которой буфер высушивают сублимацией.
8. Композиция по любому из пп. 1-7, дополнительно включающая радиоактивный металл, выбранный из группы, состоящей из 90Y, 153Sm, 165Dy, 165Er, 166Ho и 177Lu,
причем радиоактивный металл и хелатированный нацеливающий агент размещают в состоянии, в котором радиоактивный металл и хелатированный нацеливающий агент не могут контактировать друг с другом.
9. Способ получения меченного радиоактивным металлом хелатированного нацеливающего агента, включающий:
смешивание радиоактивного металла, выбранного из группы, состоящей из 90Y, 153Sm, 165Dy, 165Er, 166Ho и 177Lu, и хелатированного нацеливающего агента в присутствии по меньшей мере одного вида буфера, выбранного из группы, состоящей из бензойной кислоты, малеиновой кислоты, фумаровой кислоты, янтарной кислоты и их солей, с формированием комплекса между радиоактивным металлом и хелатированным нацеливающим агентом.
10. Лекарственное средство для диагностики или лечения заболевания, включающее комбинацию: (A) радиоактивного металла, выбранного из группы, состоящей из 90Y, 153Sm, 165Dy, 165Er, 166Ho и 177Lu; (B) хелатированного нацеливающего агента; и (C) по меньшей мере одного вида буфера, выбранного из группы, состоящей из бензойной кислоты, малеиновой кислоты, фумаровой кислоты, янтарной кислоты и их солей,
причем заболевание является мишенью хелатированного нацеливающего агента.
11. Применение комбинации: (A) радиоактивного металла, выбранного из группы, состоящей из 90Y, 153Sm, 165Dy, 165Er, 166Ho и 177Lu; (B) хелатированного нацеливающего агента; и (C) по меньшей мере одного вида буфера, выбранного из группы, состоящей из бензойной кислоты, малеиновой кислоты, фумаровой кислоты, янтарной кислоты и их солей, для получения лекарственного средства для диагностики или лечения заболевания,
причем заболевание является мишенью хелатированного нацеливающего агента.
12. Комбинация: (A) радиоактивного металла, выбранного из группы, состоящей из 90Y, 153Sm, 165Dy, 165Er, 166Ho и 177Lu; (B) хелатированного нацеливающего агента; и (C) по меньшей мере одного вида буфера, выбранного из группы, состоящей из бензойной кислоты, малеиновой кислоты, фумаровой кислоты, янтарной кислоты и их солей, для диагностики или лечения заболевания,
причем заболевание является мишенью хелатированного нацеливающего агента.
13. Способ диагностики или лечения заболевания, включающий введение комбинации: (A) радиоактивного металла, выбранного из группы, состоящей из 90Y, 153Sm, 165Dy, 165Er, 166Ho и 177Lu; (B) хелатированного нацеливающего агента; и (C) по меньшей мере одного вида буфера, выбранного из группы, состоящей из бензойной кислоты, малеиновой кислоты, фумаровой кислоты, янтарной кислоты и их солей,
причем заболевание является мишенью хелатированного нацеливающего агента.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016-161114 | 2016-08-19 | ||
| JP2016161114 | 2016-08-19 | ||
| PCT/JP2017/029696 WO2018034354A1 (ja) | 2016-08-19 | 2017-08-21 | 緩衝剤を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019105539A true RU2019105539A (ru) | 2020-09-21 |
| RU2019105539A3 RU2019105539A3 (ru) | 2020-12-18 |
| RU2757768C2 RU2757768C2 (ru) | 2021-10-21 |
Family
ID=61197279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019105539A RU2757768C2 (ru) | 2016-08-19 | 2017-08-21 | Композиция, содержащая буфер |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11951168B2 (ru) |
| EP (1) | EP3501554A4 (ru) |
| JP (1) | JP7104274B2 (ru) |
| KR (1) | KR20190039695A (ru) |
| CN (1) | CN109641069A (ru) |
| AU (1) | AU2017311925B2 (ru) |
| BR (1) | BR112019003370A2 (ru) |
| CA (1) | CA3031198A1 (ru) |
| RU (1) | RU2757768C2 (ru) |
| WO (1) | WO2018034354A1 (ru) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7060247B2 (en) | 1997-04-22 | 2006-06-13 | The Curators Of The University Of Missouri | Gastrin receptor-avid peptide conjugates |
| JPH1199524A (ja) | 1997-09-29 | 1999-04-13 | Fuji Industries:Kk | 金型クリーニング装置 |
| US20050215472A1 (en) * | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
| DE10361598A1 (de) * | 2003-12-24 | 2005-07-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Gefriergetrocknete Formulierung von Antikörperkonjugaten |
| DE102004014783A1 (de) * | 2004-03-24 | 2005-10-20 | Boehringer Ingelheim Pharma | Gefriergetrocknete Formulierung von Antikörperkonjugaten |
| EP2313504B1 (en) * | 2008-06-30 | 2015-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| KR101055700B1 (ko) * | 2009-01-28 | 2011-08-11 | 서울대학교산학협력단 | 면역세포 영상화 및 탐지를 위한 양기능성킬레이트제와 만노실 인혈청알부민의 결합체 및 그의 방사성동위원소 표지 화합물 |
| FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
| WO2011099524A1 (ja) | 2010-02-10 | 2011-08-18 | 富士フイルムＲｉファーマ株式会社 | 放射性金属標識抗カドヘリン抗体 |
| CN104768573B (zh) * | 2012-05-08 | 2017-08-29 | Trt创新有限责任公司 | 用于位点特异性uPAR靶向的177‑Lu标记肽 |
| CN108064244B (zh) * | 2014-11-14 | 2021-09-17 | 诺华股份有限公司 | 抗体药物缀合物 |
| CN105617413A (zh) | 2016-01-22 | 2016-06-01 | 北京肿瘤医院 | 核素标记mAb109单抗药物及其制备方法 |
-
2017
- 2017-08-21 EP EP17841575.8A patent/EP3501554A4/en active Pending
- 2017-08-21 WO PCT/JP2017/029696 patent/WO2018034354A1/ja unknown
- 2017-08-21 US US16/321,973 patent/US11951168B2/en active Active
- 2017-08-21 RU RU2019105539A patent/RU2757768C2/ru active
- 2017-08-21 KR KR1020197002330A patent/KR20190039695A/ko active IP Right Grant
- 2017-08-21 AU AU2017311925A patent/AU2017311925B2/en active Active
- 2017-08-21 CN CN201780050768.1A patent/CN109641069A/zh active Pending
- 2017-08-21 CA CA3031198A patent/CA3031198A1/en not_active Abandoned
- 2017-08-21 JP JP2018534445A patent/JP7104274B2/ja active Active
- 2017-08-21 BR BR112019003370-0A patent/BR112019003370A2/pt not_active IP Right Cessation
-
2024
- 2024-02-12 US US18/438,751 patent/US20240245777A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3501554A4 (en) | 2020-04-15 |
| RU2019105539A3 (ru) | 2020-12-18 |
| EP3501554A1 (en) | 2019-06-26 |
| US11951168B2 (en) | 2024-04-09 |
| AU2017311925A1 (en) | 2019-02-14 |
| BR112019003370A2 (pt) | 2019-05-21 |
| RU2757768C2 (ru) | 2021-10-21 |
| US20190175736A1 (en) | 2019-06-13 |
| AU2017311925B2 (en) | 2023-02-16 |
| CN109641069A (zh) | 2019-04-16 |
| KR20190039695A (ko) | 2019-04-15 |
| CA3031198A1 (en) | 2018-02-22 |
| US20240245777A1 (en) | 2024-07-25 |
| JP7104274B2 (ja) | 2022-07-21 |
| JPWO2018034354A1 (ja) | 2019-06-20 |
| WO2018034354A1 (ja) | 2018-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Badrising et al. | Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment | |
| Klaiber et al. | Neoadjuvant and adjuvant chemotherapy in pancreatic cancer | |
| Song et al. | Acute hematogenous osteomyelitis in children | |
| Young et al. | Maintenance chemotherapy for advanced Hodgkin's disease in remission | |
| Kim et al. | Pulmonary artery intimal sarcoma versus pulmonary artery thromboembolism: CT and clinical findings | |
| JP2017523985A5 (ru) | ||
| JP2018527884A5 (ru) | ||
| JP2015523326A5 (ru) | ||
| Mattina et al. | Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review | |
| JP2016540503A5 (ru) | ||
| JP2015517482A5 (ru) | ||
| Greenwood | Malaria vaccines: Evaluation and implementation | |
| HRP20231464T1 (hr) | Protutijela protiv tnf-alfa i njihovi funkcionalni fragmenti | |
| JP2012131808A5 (ru) | ||
| HRP20210933T1 (hr) | Dijagnostički reagensi za unaprijeđenu in vivo ili in vitro stanično-posredovanu imunološku dijagnozu tuberkuloze | |
| RU2019105539A (ru) | Композиция, содержащая буфер | |
| TWI546381B (zh) | 用以標的黑色素瘤相關抗原a3胜肽之寡核苷酸適體及其用途 | |
| DE11786796T1 (de) | Antigenpeptid und verwendung davon | |
| JP2017503161A5 (ru) | ||
| Yan et al. | Development of Y-shaped peptide for constructing nanoparticle systems targeting tumor-associated macrophages in vitro and in vivo | |
| Elwakil et al. | N-butyl-2-cyanoacrylate, iso-amyl-2-cyanoacrylate and hypertonic glucose with 72% chromated glycerin in gastric varices | |
| Kim et al. | How much progress has been made in minimally invasive surgery for gastric cancer in Korea?: a viewpoint from Korean prospective clinical trials | |
| Singh et al. | Suture granuloma: a rare differential diagnosis of residual/recurrent gastrointestinal stromal tumor of stomach | |
| Conradi et al. | Rectal cancer: open questions in 2022 current standards of clinical practice and ongoing trials | |
| Rowe et al. | The role of PET in the evaluation of musculoskeletal infections |